Moxonidine-d3

CAT:
804-HY-B0374S2
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Moxonidine-d3 - image 1

Moxonidine-d3

  • Description:

    Moxonidine-d3 (BDF5895-d3) is deuterium labeled Moxonidine (HY-B0374) . Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis[1][2][3][4][5][6][7].
  • Product Name Alternative:

    BDF5895-d3
  • UNSPSC:

    12352005
  • Target:

    Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; LDLR
  • Related Pathways:

    GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Others
  • Applications:

    Neuroscience-Neuromodulation
  • Field of Research:

    Neurological Disease; Cardiovascular Disease
  • Smiles:

    ClC1=C(NC2=NCCN2)C(OC([2H])([2H])[2H])=NC(C)=N1
  • Molecular Formula:

    C9H9D3ClN5O
  • Molecular Weight:

    244.70
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82.|[3]Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24 (4) :3857. |[4]Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409 (4) :645-50.|[5]Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126 (6) :1522-30.|[6]Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397 (1) :113-20. |[7]Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362 (1) :61-7.|[8]Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603 (1-3) :73-8.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Isotope-Labeled Compounds
  • Clinical Information:

    No Development Reported